Association of Infliximab Levels With Mucosal Healing Is Time-Dependent in Crohn’s Disease: Higher Drug Exposure Is Required Postinduction Than During Maintenance Treatment.

Association of Infliximab Levels With Mucosal Healing Is Time-Dependent in Crohn’s Disease: Higher Drug Exposure Is Required Postinduction Than During Maintenance Treatment. Inflamm Bowel Dis. 2019 Apr 01;: Authors: Feng T, Chen B, Ungar B, Qiu Y, Zhang S, He J, Lin S, He Y, Zeng Z, Ben-Horin S, Chen M, Mao R Abstract BACKGROUND: Infliximab levels have been reported to be associated with mucosal healing (MH) in Crohn’s disease (CD). However, whether the association differs between postinduction (week 14) and maintenance (week 30) has seldom been investigated. We aimed…

Read More

The Inflammatory Bowel Disease Medical Home: From Patients to Populations.

The Inflammatory Bowel Disease Medical Home: From Patients to Populations. Inflamm Bowel Dis. 2019 Apr 01;: Authors: Click B, Regueiro M Abstract With increasing emphasis on cost reduction and quality improvement, the transition to value-based care is underway. New models of health care delivery are being explored to optimize patient experience and outcomes while decreasing health care expenses. One such model is the specialty medical home (SMH), which provides multidisciplinary, high-quality care for chronic diseases with specialist involvement, such as inflammatory bowel disease (IBD). This review aims to explore the…

Read More

The Role of Early Biologic Therapy in Inflammatory Bowel Disease.

The Role of Early Biologic Therapy in Inflammatory Bowel Disease. Inflamm Bowel Dis. 2019 Apr 01;: Authors: Berg DR, Colombel JF, Ungaro R Abstract The goals for treatment of inflammatory bowel diseases (IBDs) are changing from elimination of symptoms toward complete disease control-a process that demands both clinical and endoscopic remission. This new IBD treatment paradigm has been shifting from a conventional “step-up” approach toward a more “top-down” early intervention treatment strategy. Recent studies suggest that the use of biologic agents, specifically those targeting tumor necrosis factor alpha, earlier in…

Read More

Shiga Toxin Producing Escherichia coli-Hemolytic Uremic Syndrome Mimicking Acute Severe Ulcerative Colitis in a Child With Bloody Diarrhea.

Shiga Toxin Producing Escherichia coli-Hemolytic Uremic Syndrome Mimicking Acute Severe Ulcerative Colitis in a Child With Bloody Diarrhea. Inflamm Bowel Dis. 2019 Apr 01;: Authors: Roberta N, Valentina B, Luigi M, Carmine P, Giovanni DN PMID: 30934058 [PubMed – as supplied by publisher] PubMed Link: https://www.ncbi.nlm.nih.gov/pubmed/30934058?dopt=Abstract

Read More

A Nomogram Combining Fecal Calprotectin Levels and Plasma Cytokine Profiles for Individual Prediction of Postoperative Crohn’s Disease Recurrence.

A Nomogram Combining Fecal Calprotectin Levels and Plasma Cytokine Profiles for Individual Prediction of Postoperative Crohn’s Disease Recurrence. Inflamm Bowel Dis. 2019 Mar 29;: Authors: Cerrillo E, Moret I, Iborra M, Pamies J, Hervás D, Tortosa L, Sáez-González E, Nos P, Beltrán B Abstract BACKGROUND: The aims of this study were to characterize the immune response profile in patients with Crohn’s disease (CD) and early postoperative recurrence (POR), to identify predictive biomarkers, and to develop a noninvasive predictive tool for individual estimation of POR risk. METHODS: Sixty-one patients who had…

Read More

Intestinal CD103+CD4+ and CD103+CD8+ T-Cell Subsets in the Gut of Inflammatory Bowel Disease Patients at Diagnosis and During Follow-up.

Intestinal CD103+CD4+ and CD103+CD8+ T-Cell Subsets in the Gut of Inflammatory Bowel Disease Patients at Diagnosis and During Follow-up. Inflamm Bowel Dis. 2019 Mar 27;: Authors: Roosenboom B, Wahab PJ, Smids C, Groenen MJM, van Koolwijk E, van Lochem EG, Horjus Talabur Horje CS Abstract BACKGROUND: The integrin CD103 is proposed to be a potential therapeutical target in inflammatory bowel disease (IBD), as it can form a heterodimeric integrin with β7 (Etrolizumab, anti-β7 integrin) on epithelial T cells. Therefore, we aimed to study the frequencies of different intestinal CD103+T-cell subsets,…

Read More

Microbiota Metabolite Butyrate Differentially Regulates Th1 and Th17 Cells’ Differentiation and Function in Induction of Colitis.

Microbiota Metabolite Butyrate Differentially Regulates Th1 and Th17 Cells’ Differentiation and Function in Induction of Colitis. Inflamm Bowel Dis. 2019 Mar 27;: Authors: Chen L, Sun M, Wu W, Yang W, Huang X, Xiao Y, Ma C, Xu L, Yao S, Liu Z, Cong Y Abstract BACKGROUND: How the gut microbiota regulates intestinal homeostasis is not completely clear. Gut microbiota metabolite short-chain fatty acids (SCFAs) have been reported to regulate T-cell differentiation. However, the mechanisms underlying SCFA regulation of T-cell differentiation and function remain to be investigated. METHODS: CBir1, an…

Read More

Systematic Review With Meta-analysis: Epidemiology of Nonalcoholic Fatty Liver Disease in Patients With Inflammatory Bowel Disease.

Systematic Review With Meta-analysis: Epidemiology of Nonalcoholic Fatty Liver Disease in Patients With Inflammatory Bowel Disease. Inflamm Bowel Dis. 2019 Mar 27;: Authors: Zou ZY, Shen B, Fan JG Abstract BACKGROUND: Nonalcoholic fatty liver disease (NAFLD) is increasingly identified in patients with inflammatory bowel disease (IBD), but there are few systematic reviews and meta-analyses of the studies of NAFLD in IBD patients. METHODS: MEDLINE, Web of Science, Cochrane Library, and Scopus were searched (until August 2018) to identify observational studies that reported the prevalence and risk factors for NAFLD in…

Read More

The Inflammatory Bowel Disease Symptom Inventory: A Patient-report Scale for Research and Clinical Application.

The Inflammatory Bowel Disease Symptom Inventory: A Patient-report Scale for Research and Clinical Application. Inflamm Bowel Dis. 2019 Mar 27;: Authors: Sexton KA, Walker JR, Targownik LE, Graff LA, Haviva C, Beatie BE, Petty SK, Bernstein MT, Singh H, Miller N, Bernstein CN Abstract OBJECTIVES: Existing measures of inflammatory bowel disease (IBD) symptoms are not well suited to self-report, inadequate in measurement properties, insufficiently specific, or burdensome for brief or repeated administration. We aimed to develop a patient-reported outcome measure to assess a broader range of IBD symptoms. METHODS: The…

Read More

The Relationship Between Adverse Childhood Experiences and Health Care Use in the Manitoba IBD Cohort Study.

The Relationship Between Adverse Childhood Experiences and Health Care Use in the Manitoba IBD Cohort Study. Inflamm Bowel Dis. 2019 Mar 23;: Authors: Witges KM, Bernstein CN, Sexton KA, Afifi T, Walker JR, Nugent Z, Lix LM Abstract BACKGROUND: We aimed to determine the prevalence of adverse childhood experiences (ACEs) in persons with inflammatory bowel disease (IBD) and whether having ACEs was associated with health care utilization post-IBD diagnosis. METHOD: Three hundred forty-five participants from the population-based Manitoba IBD Cohort Study self-reported ACEs (ie, physical abuse, sexual abuse, death of…

Read More
<< Go Back